Ovid Therapeutics Stock Alpha and Beta Analysis
OVID Stock | USD 1.05 0.01 0.94% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Ovid Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Ovid Therapeutics over a specified time horizon. Remember, high Ovid Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Ovid Therapeutics' market risk premium analysis include:
Beta 2.34 | Alpha (0.43) | Risk 3.79 | Sharpe Ratio (0.07) | Expected Return (0.26) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Ovid |
Ovid Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Ovid Therapeutics market risk premium is the additional return an investor will receive from holding Ovid Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Ovid Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Ovid Therapeutics' performance over market.α | -0.43 | β | 2.34 |
Ovid Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Ovid Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Ovid Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Ovid Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Ovid Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Ovid Therapeutics shares will generate the highest return on investment. By understating and applying Ovid Therapeutics stock market price indicators, traders can identify Ovid Therapeutics position entry and exit signals to maximize returns.
Ovid Therapeutics Return and Market Media
The median price of Ovid Therapeutics for the period between Sun, Aug 25, 2024 and Sat, Nov 23, 2024 is 1.15 with a coefficient of variation of 6.29. The daily time series for the period is distributed with a sample standard deviation of 0.07, arithmetic mean of 1.16, and mean deviation of 0.06. The Stock received substential amount of media coverage during this period. Price Growth (%) |
Timeline |
1 | Acquisition by Perone Thomas Michael of 175000 shares of Ovid Therapeutics at 2.72 subject to Rule 16b-3 | 08/30/2024 |
2 | Disposition of 70000 shares by Alexander Margaret A. of Ovid Therapeutics at 3.73 subject to Rule 16b-3 | 09/09/2024 |
3 | Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth - StockTitan | 09/11/2024 |
4 | Ovid stock gets boost from promising OV329 toxicity profile - B.Riley - Investing.com | 09/27/2024 |
5 | Ovid Therapeutics Inc. Given Consensus Recommendation of Moderate Buy by Analysts | 10/11/2024 |
6 | Acquisition by Friedman Bart of 69424 shares of Ovid Therapeutics subject to Rule 16b-3 | 10/24/2024 |
7 | Acquisition by Williams Douglas E of 13250 shares of Ovid Therapeutics at 5.29 subject to Rule 16b-3 | 10/25/2024 |
8 | Explainer-How Trumps second administration affects business Musk, tariffs and more | 11/06/2024 |
9 | Ovid Therapeutics earnings beat, revenue topped estimates | 11/12/2024 |
10 | How controversial is Trumps pick of RFK Jr as US health secretary | 11/15/2024 |
11 | B. Riley Predicts Reduced Earnings for Ovid Therapeutics | 11/20/2024 |
About Ovid Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Ovid or other stocks. Alpha measures the amount that position in Ovid Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
2023 | 2024 (projected) | Days Sales Outstanding | 3.69 | 3.28 | PTB Ratio | 2.59 | 3.82 |
Ovid Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Ovid Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ovid Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Ovid Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Ovid Therapeutics. Please utilize our Beneish M Score to check the likelihood of Ovid Therapeutics' management manipulating its earnings.
11th of March 2024 Upcoming Quarterly Report | View | |
3rd of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
11th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Ovid Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Ovid Therapeutics Backtesting, Ovid Therapeutics Valuation, Ovid Therapeutics Correlation, Ovid Therapeutics Hype Analysis, Ovid Therapeutics Volatility, Ovid Therapeutics History and analyze Ovid Therapeutics Performance. For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Ovid Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.